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Lysosomal storage diseases are a group of inherited and acquired disorders with different clinical manifestations, affecting mammals 30, 43, 49, 97 and birds. 16, 36, 53, 59 Depending on the mutation site and/or defective gene, they may be presented as an infantile or an adult form. They may be manifested as a neurological disorder, hepatosplenomegaly, cloudy corneas or by skeletal abnormalities and as a combination of the above. Often, their clinical presentations resemble many other nonlysosomal disorders. It is very likely that more lysosomal disorders occur in animals than are currently recognized. The purpose of this paper is to review morphological, biochemical, and molecular biology approaches for the diagnosis of lysosomal storage diseases.
The lysosome is the primary disposal and recycling center of cells. It degrades cellular and extracellular macromolecules, providing amino acids, fatty acids, nucleic acids, and carbohydrate residues for reutilization in cellular synthesis. Lysosomal storage diseases are characterized primarily by deficient activity of a lysosomal hydrolase, 54, 97 and in most cases, by intralysosomal accumulation of one or more undegraded substrates in affected cells.
Most lysosomal hydrolases are soluble proteins, except glucocerebrosidase and acid phosphatase, which are associated with the lysosomal membrane. 78 However, these diseases may also be caused by a deficiency of a protein activator (saposin), 93 by amino acid modification that results in multiple hydrolase (e.g., sulfatase) deficiencies, 96 by abnormal enzyme targeting, 57 by deficiency of a protective protein, 29 by defective transport of the lysosomal membrane (a process that mediates the exit of several different degraded products from lysosomes), 34 or they may be due to abnormal transport into lysosomes. 12, 24, 95 It is noteworthy that there are several lysosomal disorders that are clinically well documented but for which the biochemical or molecular biological abnormalities are unknown. In humans, more than 40 genetically determined lysosomal storage disorders have been described, 88 whereas in animals, there are only 30 conditions in which the deficient enzyme activity has been documented and reported. It is also noteworthy that, in animals, only 1 example of deficiency in protein activator, 27, 46 and possible deficiency of a protective protein, 55 has been reported. In addition, several cases of unclassified lysosomal storage disease have been observed in animals, 32 (Axthelm et al., Japanese Macaque; Alroy et al., Lhasa Apso dog and black bear [unpublished observations]). Recently, 2 new conditions have been identified as lysosomal storage diseases. Pycnodysostosis, a rare skeletal disorder with which the French painter ToulouseLautrec was retrospectively diagnosed, has been attributed to deficiency of cathepsin K. 35 Hyaluronidase deficiency was first recognized and identified as a lysosomal storage disease in 1996. 76 In contrast, deficiency of lysosomal acid phosphatase was first recognized about 25 years ago. 73 Compared to the majority of diseases, little was known about the pathobiology of this condition until a mouse model, deficient in tartrate-sensitive acid phosphatase, was generated. 92 Table 1 lists 10 different inherited and acquired mechanisms that are currently known to cause lysosomal disease in humans and animals. Table 2 summerizes the inherited lysosomal storage diseases, their eponyms, the primary deficiency, the stored substrates, the major organs, and the corresponding disease in animals.
The manifestations of many of these storage diseases vary depending on the residual activity of the mutated enzyme, which is often determined by the type and the site of the genetic mutation. 77 Normally, most lysosomal hydrolases are present at sufficiently high activity that their respective substrates do not accumulate. Accumulation of undegraded substrate occurs only when the residual activity is below the critical threshold of 10-15% of normal enzyme activity. 60 Depending on the nature of the defective enzyme and the type and site of the mutation, there may be great differences in the age of onset, severity of the manifestations, and organ involvement for each lysosomal storage disease. Furthermore, since the genetic defect, whether it be deficient enzyme activity, abnormal en- zyme targeting, or impaired product efflux, etc., occurs in all cell types of affected individuals, the amount of abnormal storage in specific cells is determined by the type and amount of available substrates that are recycled in these cells. The substrate load in each cell is influenced by cell membrane composition, rate of membrane recycling, cellular catabolism, phagocytic ability of affected cells, and the nature of the phagocytosed substrates. 22 As a consequence, different cell types are affected differently, and some may not show any obvious effects. Generally, 2 types of changes are observed in lysosomal storage disorders. The primary changes are the direct consequence of abnormal accumulation of substrates or catabolites in lysosomes. The secondary changes are likely to result from disrupted recycling and are manifested in abnormal cellular and extracellular products. 4, 45, 52, 65, 68, 74, 75, 87, 102 The physiological consequences of both primary and secondary processes are often similar despite the fact that the genetic defect and stored substrate(s) are specific to each disease. Thus, many different lysosomal disorders display a similar clinical presentation.
In some cases, a specific mechanism for storageinduced cell death has been identified. Thus, in Krabbe disease, the abnormal lysosomal accumulation of galactosylsphingosine, i.e., psychosine, 40, 101 leads to programmed cell death via inhibition of protein kinase C. 40, 80 In other storage diseases, the abnormal storage results in severe impairment of cellular structure and function. 44 In addition, while in most cell types expression of lysosomal hydrolases is intralysosomal, in osteoclasts, the lysosomal hydrolases are expressed at the ruffled border. 13, 86, 105 This results in the unique manifestation of skeletal lesions seen in several lysosomal storage diseases.
In the majority of lysosomal disorders, the specific diagnosis can be established by demonstrating deficient enzyme activity in plasma, leukocytes, or cultured fibroblasts. However, there are several lysosomal storage disorders in which neither the nature of the storage material nor the enzymatic defect are known. The situation is complicated by the occurrence of pseudodeficiency of lysosomal hydrolases in several individuals who remain clinically asymptomatic. 38, 56 In addition, significant reduction of several lysosomal hydrolase activities was observed in leukocytes of patients with phosphomannomutase deficiency, i.e., carbohydrate-deficient glycoprotein syndrome type IA. 14 Furthermore, in a recent study of cost effectiveness in the diagnosis of lysosomal storage diseases, less then 10% of the individuals in which a lysosomal storage disease was considered were actually affected by one. In addition, multiple enzyme activity assays are expensive. 88 The current paper will provide an economic guideline for prenatal, as well as ante-and postmortem, diagnosis of lysosomal storage diseases.
Following breeding of unknown or suspected carriers, the diagnosis of a lysosomal storage disorder may be established during pregnancy 28, 62, 66 or at birth using biochemical, 28 morphophological, 6, 11 and molecular biology techniques. 62 Clinical presentation of individuals with progressive neurological deficiency, retinitis pigmentosa regardless of the age of onset, ab-normal skeletal development with or without neurological signs, cloudy cornea associated with dysmorphic features, progressive hepatosplenomegaly, or cardiomegaly with or without the above listed features should always indicate lysosomal storage disease as a possibility in the differential diagnosis.
For the infantile or juvenile forms of a storage disease in which the stored catabolites include partially degraded oligosaccharides, an initial laboratory examination of an air-dried blood smear stained with Wright-Giemsa will usually identify vacuolated lymphocytes or monocytes. Such conditions include ␣-mannosidosis ( Fig. 1) , 3 ␤-mannosidosis, G M1 -gangliosidosis, 6 G M2 -gangliosidosis (i.e., Sandhoff disease), and mucolipidoses II and III. 41 In mucopolysaccharidoses, the vacuoles contain metachromatic granules in lymphocytes, neutrophils, eosinophils, and monocytes ( Fig. 2) . 3, 41 Staining of corresponding blood smears with acid phosphatase (Fig. 3 ) can help confirm that the vacuoles are lysosomes.
Diagnosis of mucopolysaccharidoses and diseases with interrupted catabolism of oligosaccharides can be determined by urine analysis. Several different methods can be used for urinary glycosaminoglycan analysis. 85 These include a spot test that is quick, inexpensive, and useful for initial evaluation, 17 but both false negatives and false positives have been noted. Other methods that are quatitative can be used, e.g., the determination of total urinary glycosaminoglycans by the uronic acid method, electrophoresis of urinary glycosaminoglycans (Fig. 4) , 103 fluorophore-labeled carbohydrate polyacrylamide gel electrophoresis (PAGE), 37 and gradient-PAGE before and after digestion with specific lysosomal hydrolases. 21 A positive spot test plus presence of vacuolated leukocytes containing metachromatic granules is consistent with mucopolysaccharidoses. Comparison of these observations with the clinical manifestation, the severity of dysostosis multiplex, presence or absence of cloudy cornea, and occurrence of neurological signs can reduce the number of enzyme assays required for definitive etiological diagnosis. Diagnosis of glycoprotein storage diseases can be effectively achieved by analysis of urine oligosaccharides using thin-layer chromatography (TLC) (Fig. 5 ) or high-pressure liquid chromatography (HPLC) (Fig. 6 ). Two-dimensional TLC is also useful. 1 For prenatal diagnosis, allantoic fluid is sampled and used instead of urine. 28 Glycoprotein storage diseases include ␣-and ␤-mannosidosis, fucosidosis, sialidosis, aspartylglucosaminuria, galactosialidosis, free sialic acid storage, some forms of G M1 -gangliosidosis, disease resulting from deficiency in the activity of ␣-Nacetylgalactosaminidase, and Sandhoff disease. The same analytical techniques, i.e., TLC and HPLC, of oligosaccharides in urine (or in other body fluids or postmortem in tissue extracts) are also used for the diagnosis of acquired glycoprotein storage diseases such as swainsonine toxicosis resulting from the ingestion of locoweed. 107, 108 Furthermore, because the severity of swainsonine toxicosis depends on the amount of toxin ingested, the toxicosis can be reversed if the diet is corrected. In such situations, TLC and HPLC of urine oligosaccharides are also used to monitor the progression of the disease (Fig. 5) .
In humans, examination of skin biopsies by electron microscopy (EM) was found to be a cost effective tool in the diagnosis of lysosomal storage disorders. Currently, it is the only diagnostic method for the various forms and variants of neuronal ceroid lipofuscinosis (NCL) and mucolipidosis IV. 88 Skin contains numerous cell types of ectodermal, endodermal, and mesodermal origin, including neural elements. Table 3 lists the various cell types found in skin. Electron microscopy proved to be a highly sensitive diagnostic method with very few false-negative results and was useful in identifying a new lysosomal storage disorder, i.e., hyaluronidase deficiency. 88 It is an efficient and rapid procedure. Although EM is more expensive than a single enzyme assay, it can exclude more than 90% of the cases in which the possibility of a lysosomal disorder is being considered. Further, the morphological findings reduce the number of enzyme assays needed for final diagnosis. Thus, EM provides a cost effective method for the diagnosis of lysosomal storage diseases. 88 The morphologic diagnosis of a lysosomal storage disease by EM is established by the observation of numerous and enlarged secondary lysosomes in affected cells. Although the genetic defect is ubiquitous, the morphologic manifestation is determined by the chemical structure and amount of substrate that is recycled by the cell. 22 By identifying the types of affected cells and the morphological appearance of the storage material, it is possible to determine if the defect interferes with catabolism of lipids, mucopolysaccharides, glycoproteins, and/or glycolipids. Furthermore, by demonstrating intralysosomal lipid storage, it is possible to exclude neutral lipid storage diseases that share several clinical and morphological features, including hepatosplenomegaly and vacuolated leukocytes, with lysosomal storage disease but in which the storage is not actually in lysosomes. 51, 72 Deficient activity of acid lipase is manifested by lysosomal storage of neutral lipids and cholesterol clefts in affected cells, 39, 88 whereas deficiency of ceramidase reveals banana and crystal-shaped secondary lysosomes. 88 In mucopolysaccharidoses, mesenchymal cells are the most severely affected. The lysosomes contain fibrillar material, and occasionally, lamellated structures are seen within the same lysosome (Fig. 7) . Deficient activity of an enzyme that degrades glyco- proteins effects all cell types, and the lysosomes contain either fine fibrillar material or appear empty (Fig.  8) . Storage of gangliosides is characterized by the occurrence of fine lamellated membrane structures (finger prints or as Zebra bodies) (Fig. 9) . Deficient activity of an enzyme that degrades both glycolipids and glycoproteins, such as ␣-fucosidase or ␤-galactosidase, will cause some cells to have empty-appearing lysosomes or lysosomes containing fine fibrillar material, while in other cells, lysosomes will contain lamellated membrane structures. 88 In the various forms of Niemann-Pick disease, the stored sphingomyelin and cholesterol appear as coarse lamellated membrane structures. Intralysosomal accumulation of twisted microtubules is indicative for the accumulation of glucocerebrosides or galactosylceramide, which occur in Gaucher disease 19 and Krabbe disease, respectively. 100 Enlarged lysosomes filled with glycogen particles are characteristic for Pompe disease. Storage of curvilinear material is the diagnostic feature for several forms of NCL, 42, 48, 88 while the accumulation of granular osmiophilic deposits (GRODs) indicates storage of proteins, as seen in the human 90 and infantile sheep form of NCL, 47 and also seen in a patient with late infantile onset (Alroy, unpublished observation) and in 3-and 4-year-old miniature Schnauzers. 81 Currently, assay of lysosomal hydrolase activity is the only definitive diagnostic method for most of the lysosomal storage disorders. It is useful in identifying deficient activity of a single hydrolase or of multiple hydrolases as in mucolipidosis II and III. The enzyme sources most used are isolated leukocytes or cultured dermal fibroblasts. Biochemical approaches for the diagnosis of lysosomal storage disorders have been described in an excellent detailed review. 110 This review includes the methods of collecting, storing, and transporting of blood and cultured fibroblasts, the enzymatic assays, and the synthetic and natural reagents needed for the diagnosis of 20 different disorders. Furthermore, it includes biochemical methods other than enzymatic ones, such as the cholesterol esterification assay, which is the current biochemical method for the diagnosis of Niemann-Pick C, and also the 14 C-stearic acid-sulfatide loading assay designed to confirm the diagnosis of metachromatic leukodystrophy and to differentiate pseudodeficiency from true deficiency. Rarely, the diagnosis of a lysosomal storage disorder is first determined during histopathological examination of an autopsy/necropsy tissue. However, in these cases, the primary nature of the condition is usually unknown, and it is essential for genetic counseling as well as for developing animal models that the primary defect be ascertained. In cases where frozen tissues such as brain, liver, kidney, etc., are available, the measurement of lysosomal hydrolase activity can be compared to that in an age-matched control.
In diseases in which there is a deficiency of sphingolipid activator proteins (SAP) including deficiencies in G M2 activator, sulfatide activator (i.e., SAP-B), and Gaucher activator (i.e., SAP-C), an enzyme assay is not applicable. In these conditions, the diagnosis is made by determination of the activator protein levels in a tissue extract or on a cultured fibroblast extract 93 using an ELISA method.
In the case of G M1 gangliosidosis, it is noteworthy that the identification of a carrier could be achieved by enzyme assay of leukocytes or cultured fibroblasts. In the 1980s, G M1 -gangliosidosis was identified in Portuguese Water Dogs in the USA. Extensive studies of blood samples from 2,120 dogs revealed 11½% of the dogs as presumptive carriers (Bell and Raghavan, unpublished observations). Following identification of the presumptive carrier dogs, the breeding program was changed and they were excluded from further breeding. However, occasionally it is difficult to distinguish between putative carriers and noncarriers. 71 In studies of ␤-galactosidase activity in leukocytes from a known carrier Portuguese Water Dog that had offspring affected with G M1 -gangliosidosis, the enzyme activity was within the normal range. Further inquiry revealed that the dog was treated for a long period with corticosteroid (Raghavan, Bell, and Alroy, unpublished observation). These false-negative results were due to the lymphopenia and an increased amount of older neutrophils in the blood samples.
In cases where the only specimens that are available are paraffin-embedded tissue blocks and formalinfixed tissues, a combination of histopathology, lectin histochemistry, electron microscopy, and lipid extraction can provide the diagnosis of most but not all lysosomal storage diseases. Lipid extraction, ganglioside separation, and TLC can be done on a formalin-fixed tissue. 5 Histopathological examination of paraffin and frozen sections stained with various reagents such as hematoxylin and eosin (HE), luxol fast blue (LFB), periodic acid-schiff (PAS), and sudan black is useful for general characterization of the storage material but not for a definitive diagnosis. Staining of affected cells with sudan black indicates the general presence of lipid, and staining with LFB identifies the presence of polar lipids. 83 Cytoplasmic staining with PAS, which is diastase resistant, indicates the presence of carbohydrates containing vicinal glycol groups 64 or unsaturated lipids that are retained in paraffin sections (i.e., plasmal reaction). 82 The presence of autofluorescent material may be due to the storage of various proteins 84 and is not diagnostic for neuronal ceroid lipofuscinosis. An example is autofluorescence that was seen in a 3½-year-old child with Hunter disease (MPS-II) (Fig.  10) .
Lectin histochemistry is a useful method for identification of some lysosomal storage disorders. Lectins are proteins and glycoproteins that have known sugarbinding specificities. When they are conjugated directly or indirectly to a visualant (i.e., enzymes, electron-dense metals, or a fluorescent dye), they are useful for identifying in situ the storage of compounds containing specific carbohydrate residues. 2 Lectin staining of glycoconjugates in paraffin sections permits the identification of carbohydrate residues in glycoproteins and oligosaccharides that are retained in the tissue section after delipidation of the tissue during paraffin processing. 8 By using lectin histochemistry, ␣-mannosidosis was diagnosed in an 11-week-old Blue Persian kitten 10 years after necropsy. Following this, 7 presumptive carriers were identified, bred, and the disease was reproduced. 9 At the time of necropsy, the possibility of storage disease was discussed but could not be confirmed due to lack of specimens for biochemical diagnosis. In patients with ␣-mannosidosis, affected cells stain with Concanavalia ensiformis agglutinin (Con A), wheat germ agglutinin (WGA), and succinylated-WGA (S-WGA) (Fig. 11) while the affected cells in ␤-mannosidosis do not stain with any of the above lectins. It is notworthy that, in acquired ␣-mannosidosis, i.e., swainsonine toxicosis, the affected cells stained with the same lectin as in the inherited disease. 7 In human fucosidosis, the affected cells stain with Ulex europeus agglutinin-I (UEA-I) but not in the corresponding canine disease. The difference between the 2 species is attributed to the molecular location in the stored material of the unhydrolyzed ␣-fucosyl residues. 2 In sialidosis and free sialic acid storage disease, the affected cells stained with WGA. 8, 89 The diagnosis of some glycolipid storage diseases can be achieved with lectin histochemistry only on frozen sections. 10 In G M1 -gangliosidosis, globoid cell leukodystrophy, and Fabry disease, the stored glycolipid can be demonstrated only on frozen sections with Ricinus communis agglutinin-I (RCA-I) and Griffonia simplicifolia-I (GS-I), respectively. 10 During deparaffination of paraffin sections with xylene, glycolipids such as G M1 -gangliosides and galactocerebrosides, which both contain terminal nonreducing ␤-galactosyl residues, or globotriosylceramide and galactobiosylceramide, which instead have ␣-galactosyl residues, are extracted and therefore cannot be identified.
Genetic analysis is currently used in various laboratories for pre-and postnatal diagnosis of lysosomal disorders and for identification of carriers within a population where the mutation is well defined and where the defect occurs with a high frequency. 20 However, for both practical and economical reasons, it is not the method of choice. The first reason is that the nature of the biochemical defect and the identity of the storage material must both be defined before a genetic analysis can begin. Second, the type of mutation should also be characterized. The rate of identification of new mutations is increasing exponentially. For example, in 1989, the clinical manifestations of deficient activity of ␤-hexosaminidase A (i.e., Tay-Sachs disease and its variants) were correlated to 7 different mutations on the ␣-subunit gene. 77 By 1997, approximately 73 different mutations had been identified. 31 In Gaucher disease, the number of known mutations increased within a year from 79 to 109. 18 Heterogeneity in clinical manifestation has been described in feline ␣-mannosidosis, 26 G M2 -gangliosidosis (Sandhoff disease), 25, 79 canine G M1 -gangliosidosis, 6, 91 and in a family of Nubian goats with mucopolysaccharidosis IIID. 50 These different clinical manifestations may represent different mutations, but they may also represent differences in the efficiency of alternative catabolic pathways. There have been no genetic studies that could satisfactorily explain all the differences observed in clinical manifestations within the same herd of Nubian goats. To date, mutations have been identified in dogs and Rhesus monkeys with globoid cell leukodystro-phy, 67, 106 in dogs with fucosidosis, 98 in Portuguese Water Dogs with G M1 -gangliosidosis (Raghavan et al., unpublished observation), and in cats with G M2 -gangliosidosis. 70 In cats 15 and cattle 104 with ␣-mannosidosis, 2 different mutations have been identified that led to different phenotypic expression. Other mutations causing lysosomal storage disease have been identified in dogs with mucopolysaccharidosis I, 69 in goats with mucopolysaccharidosis-IIID 23 and ␤-mannosidosis, 63 in cattle with ␤-mannosidosis, 61 in rats with mucopolysaccharidosis VI, 58 in cats and mice with mucopolysaccharidosis VII, 33, 94 and in Japanese quails with type II glycogen storage disease (i.e., lysosomal). 59 However, if a mutated gene that results in lysosomal storage disease has been identified in a relatively small, inbred population such as in fucosidosis, the polymerase chain reaction can be a useful tool for control and eradication of disease. 99 In conclusion, this review outlines the cost effective steps that are necessary for the identification of lysosomal storage diseases, the optimal approach for diagnosis of each type of disease, and some approaches toward the elimination of a mutated gene from the corresponding breeding population.
